BioSpace News Archive

Regulatory News: Innate Pharma SA announced that IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer.

Lexaria Bioscience Corp. is pleased to announce a significant exclusive* commercial licensing agreement in Japan with Premier Wellness Science Co., Ltd., (“Premier”).

Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA at the 2022 American Society of Clinical Oncology Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.

The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations, including one oral and two poster presentations, highlighting data from exploratory and pooled analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

Provention Bio, Inc. announced that the Company granted stock options to eight new employees to purchase an aggregate of 166,000 shares of common stock.

OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced new clinical data from an investigator-sponsored Phase 2 trial evaluating bavituximab combined with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it entered into an exclusive collaboration with the American Academy of Sleep Medicine (AASM) Foundation, to support its 2022 Young Investigators Research Forum (YIRF).

Merus N.V. announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 43rd Annual Global Healthcare Conference.